We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current TRXPF market cap is 707.62M. The company's latest EPS is JPY 143.0208 and P/E is 0.17.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Revenue | 43B | 41.7B | 46.99B | 48.9B | 54.64B |
| Operating Income | 1.43B | 4.7B | 4.6B | 5.48B | 4.99B |
| Net Income | 27.37B | 3.5B | 3.37B | 3.94B | 4.12B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Total Assets | 139.94B | 126.03B | 130.81B | 133.69B | 133.43B |
| Total Liabilities | 26.82B | 10.94B | 13.8B | 14.46B | 13.3B |
| Total Equity | 113.13B | 115.09B | 117.02B | 119.23B | 120.13B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | JPY (¥) | |
| Operating | 42.5B | -3.44B | -160M | 2.42B | -3.13B |
| Investing | 2.1B | 7.63B | -1.5B | -13.68B | -3.78B |
| Financing | -1.43B | -1.43B | -1.55B | -1.7B | -3.84B |
| Market Cap | 707.62M |
| Price to Earnings Ratio | 0.17 |
| Price to Sales Ratio | 0.01 |
| Price to Cash Ratio | 0.14 |
| Price to Book Ratio | 0.01 |
| Dividend Yield | - |
| Shares Outstanding | 28.8M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 2.69k (100%) |
| Company Name | Torii Pharmaceutical Co (PK) |
| Address |
3-4-1 nihonbashi honcho chuo, tokyo 103-8439 |
| Website | https://www.torii.co.jp |
| Industry | pharmaceutical diversified (H2) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
